Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Adv Cancer Res. 2023;159:185-201. doi: 10.1016/bs.acr.2023.02.009. Epub 2023 Mar 13.
Underrepresented minority patients with pancreatic cancer have differential access to cancer treatments, including clinical trials. The successful conduct and completion of clinical trials is critical to improve outcomes for patients with pancreatic cancer. Therefore, it is essential to consider how to maximize eligibility of patients for both therapeutic and non-therapeutic clinical trials. It is important for clinicians and for the health system to understand individual-, clinician-, and system-level barriers to recruitment, enrollment, and completion of clinical trials to alleviate bias. Understanding strategies that lead to improved enrollment of underrepresented minorities, socioeconomically disadvantaged individuals, and underserved communities will improve generalizability of cancer clinical trials and advance health equity.
代表性不足的少数族裔胰腺癌患者在获得癌症治疗方面存在差异，包括临床试验。成功开展和完成临床试验对于改善胰腺癌患者的预后至关重要。因此，必须考虑如何最大限度地提高患者参加治疗性和非治疗性临床试验的资格。临床医生和医疗体系了解招募、入组和完成临床试验的个体、临床医生和体系层面的障碍对于减轻偏见至关重要。了解导致代表性不足的少数族裔、社会经济弱势群体和服务不足社区入组率提高的策略将提高癌症临床试验的普遍性，并促进健康公平。
